Bivalent Human Papillomavirus (HPV) Vaccine Effectiveness Correlates With Phylogenetic Distance From HPV Vaccine Types 16 and 18

To substantiate cross-protection reported across AS04-adjuvanted bivalent human papillomavirus (HPV) vaccine (2vHPV) studies, we reevaluated vaccine effectiveness against type-specific HPV positivity as a function of phylogenetic distance to vaccine target types HPV-16 and -18. We provide evidence o...

Full description

Saved in:
Bibliographic Details
Published in:The Journal of infectious diseases 2019-08, Vol.220 (7), p.1141-1146
Main Authors: Bogaards, Johannes A., Van Der Weele, Pascal, Woestenberg, Petra J., Van Benthem, Birgit H. B., King, Audrey J.
Format: Article
Language:English
Subjects:
Adolescent
Antigens
Capsid Proteins - genetics
Cross Protection - genetics
Cross-protection
Cross-Sectional Studies
Female
Genotype
Human papillomavirus
Human papillomavirus 16 - genetics
Human papillomavirus 16 - immunology
Human papillomavirus 18 - genetics
Human papillomavirus 18 - immunology
Humans
Major and Brief Reports
Netherlands
Papanicolaou Test
Papillomavirus Infections - prevention & control
Papillomavirus Vaccines - immunology
Papillomavirus Vaccines - therapeutic use
Phylogenetics
Phylogeny
Polymerase Chain Reaction
Treatment Outcome
Vaccine efficacy
VACCINES
Vaginal Smears
Young Adult
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:To substantiate cross-protection reported across AS04-adjuvanted bivalent human papillomavirus (HPV) vaccine (2vHPV) studies, we reevaluated vaccine effectiveness against type-specific HPV positivity as a function of phylogenetic distance to vaccine target types HPV-16 and -18. We provide evidence of sustained cross-protection up to 8 years postvaccination in a high-risk population in the Netherlands. Moreover, our findings suggest that genomic distance better explains cross-protection than distance measures based on capsid antigens only. Taken together, 2vHPV is predicted to provide partial cross-protection against HPV-31, -33, -35, -45, -52, and possibly -58, that is, acknowledged oncogenic types with close phylogenetic relationships to HPV-16 or -18.
ISSN:0022-1899
1537-6613
DOI:10.1093/infdis/jiz280